636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study

• Scott Antonia,
• Jeffrey Clarke,
• Thomas Stinchcombe,
• John Hartman,
• Jeffrey Crawford,
• Monica Bodd,
• Susan Locke,
• Kris Herring,
• Neal Ready,
• Jesse Troy,
• Chakita Williams,
• Steven Wolf,
• Thomas LeBlanc

Affiliations

Scott Antonia

Aff8 grid.468198.a0000 0000 9891 5233H. Lee Moffit Cancer Center and Research Institute USA

Jeffrey Clarke

3Duke, Durham, NC, USA

Thomas Stinchcombe

2Duke University, Durham, NC, USA

John Hartman

2Bristol Myers Squibb, Lawrenceville, NJ, USA

Jeffrey Crawford

Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA

Monica Bodd

1Duke University School of Medicine, Durham, NC, United States

Susan Locke

2Duke Cancer Institute, Durham, NC, United States

Kris Herring

2Duke Cancer Institute, Durham, NC, United States

Neal Ready

2Duke Cancer Institute, Durham, NC, United States

Jesse Troy

1Duke University School of Medicine, Durham, NC, United States

Chakita Williams

3Bristol Myers Squibb, Lawrenceville, NJ, United States

Steven Wolf

1Duke University School of Medicine, Durham, NC, United States

Thomas LeBlanc

2Duke Cancer Institute, Durham, NC, United States